Organon & Co.OGN

Organon & Co. Segments Disclosure

10-KFiled Feb 24, 20263 min read
Product and Geographic Information
Revenues of the Company’s products were as follows:
Year Ended December 31,
202520242023
($ in millions)U.S.Int’lTotalU.S.Int’lTotalU.S.Int'lTotal
Women’s Health
Nexplanon/Implanon NXT$610 $311 $921 $672 $291 $963 $572 $257 $830 
Follistim AQ112 152 264 84 152 237 125 136 262 
NuvaRing
19 72 91 39 75 115 90 86 176 
Ganirelix Acetate Injection
12 89 101 20 89 109 — 134 134 
Marvelon/Mercilon
— 127 127 — 134 134 19 91 110 
Jada73 1 74 60 1 61 43 — 43 
Other Women’s Health (1)
65 109 174 56 104 158 48 101 147 
General Medicines
Biosimilars
Renflexis183 69 251 219 55 274 234 43 278 
Hadlima166 62 228 104 38 142 17 26 44 
Ontruzant15 84 99 29 112 141 46 109 155 
Brenzys— 80 80 — 77 77 — 73 73 
Other Biosimilars (1)
17 16 33 — 28 28 — 43 43 
Established Brands
Cardiovascular
Atozet— 324 324 — 473 473 — 519 519 
Zetia5 337 342 7 310 317 8 314 322 
Cozaar/Hyzaar8 211 219 9 234 243 10 272 281 
Vytorin4 96 100 6 102 108 6 124 129 
Rosuzet— 24 24 — 49 49 — 70 70 
Other Cardiovascular (1)
3 124 126 2 130 133 2 136 139 
Respiratory
Singulair8 244 252 9 350 359 11 393 404 
Nasonex— 261 262 — 276 276 — 266 266 
Dulera113 39 153 162 42 203 156 38 194 
Clarinex2 121 123 3 125 127 5 132 136 
Other Respiratory (1)
42 12 52 38 13 53 49 14 64 
Non-Opioid Pain, Bone and Dermatology
Arcoxia— 265 265 — 270 270 — 257 257 
Fosamax2 141 143 3 147 151 3 156 159 
Diprospan— 150 150 — 139 139 — 91 91 
Vtama
111 17 128 10 1 12 — — — 
Other Non-Opioid Pain, Bone and Dermatology (1)
16 285 301 19 279 295 14 261 275 
Other
Propecia6 112 118 6 105 111 7 118 125 
Emgality— 174 174 — 107 107 — — — 
Proscar1 96 97 1 94 95 1 96 97 
Other (1)
10 327 338 14 314 328 13 308 319 
Other (2)
1 80 82 — 115 115 (1)121 121 
Revenues$1,604 $4,612 $6,216 $1,572 $4,831 $6,403 $1,478 $4,785 $6,263 
Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately.
(2) Includes manufacturing sales to third parties.
Revenues by geographic area where derived are as follows:
Year Ended
December 31,
($ in millions)202520242023
Europe and Canada$1,618 $1,763 $1,673 
United States1,604 1,572 1,478 
Asia Pacific and Japan1,000 1,050 1,129 
China829 847 864 
Latin America, Middle East, Russia, and Africa
1,072 1,034 965 
Other (1)
93 137 154 
Revenues$6,216 $6,403 $6,263 
(1) Includes manufacturing sales to third parties.

As of December 31, 2025, approximately 75% of the Company’s long-lived fixed assets are located in Europe and Canada, and 17% are in the United States. The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.

Historical Timeline

Fiscal YearFiled
2025Feb 24, 2026Showing above
2024Feb 28, 2025
2023Feb 26, 2024
2022Feb 27, 2023
2021Mar 21, 2022

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesRevenueEarnings Per SharePP&EDebtCommitmentsStock CompensationNew Standards